UNSPSC 51422436: Hydrocortisone valerate

This classification denotes a therapeutic glucocorticoid with the molecular formula C26H38O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68717P8FUZ, chemically known as 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione but more generally known as hydrocortisone valerate, which bears US NIH Compound Identifier 5754. European Medicines Agency schedules Hydrocortisone valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02570MIG.

UNSPSC 51422436 Hydrocortisone valerate is a Commodity code nominally covering a topical corticosteroid pharmaceutical product, but the recent state and local opportunities tagged under this code do not align with the procurement of hydrocortisone valerate itself. Instead, the opportunities reflect solicitations for naloxone, drug deactivation systems, and direct-to-manufacturer prescription program capabilities—products and services unrelated to the stated code scope. The mismatch suggests either a tagging error in the underlying opportunity records or that this code has been repurposed by issuers for broader pharmaceutical procurement activity. State and local buying under this code as currently tagged includes opioid-reversal medications, controlled-substance disposal systems, and pharmacy benefit management infrastructure rather than dermatological corticosteroid products. Issuing bodies include county health departments and state health and human services agencies conducting population-health and addiction-response procurement.

Recent activity concentrates in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries required to the Seminole County Community Health Building in Sanford and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and group purchasing organizations, with responses due April 3, 2026. The Texas RFI functions as exploratory market intelligence rather than a formal competitive solicitation, designed to inform the state's future procurement strategy before issuing a formal RFP. Neither opportunity specifies set-aside designations, and both require standard compliance certifications including E-Verify and drug-free workplace verification. The Seminole County contract carries a two-year initial term with a one-year renewal option; the Texas RFI carries no award value or binding timeline at this stage.